Status: In progress

In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation

  • Deadline to file a claim: 02/17/2024
  • Proof of Purchase Required: Yes
  • Potential Individual Reward: Varies
  • Total Settlement Amount: $30 million
  • Locations
    • Alabama
    • Alaska
    • Arizona
    • Arkansas
    • Colorado
    • Delaware
    • District of Columbia
    • California
    • Florida
    • Georgia
    • Hawaii
    • Idaho
    • Illinois
    • Kansas
    • Nebraska
    • Kentucky
    • Louisiana
    • Maine
    • Maryland
    • Massachusetts
    • Michigan
    • Minnesota
    • Mississippi
    • Missouri
    • Montana
    • Nevada
    • New Hampshire
    • New Jersey
    • Connecticut
    • New Mexico
    • New York
    • North Carolina
    • North Dakota
    • Oklahoma
    • Oregon
    • Pennsylvania
    • Rhode Island
    • South Carolina
    • South Dakota
    • Tennessee
    • Texas
    • Utah
    • Vermont
    • Virginia
    • Washington
    • West Virginia
    • Wisconsin
    • Wyoming

Status: In progress

In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation

  • Deadline to file a claim: 02/17/2024
  • Proof of Purchase Required: Yes
  • Potential Individual Reward: Varies
  • Total Settlement Amount: $30 million
  • Locations
    • Alabama
    • Alaska
    • Arizona
    • Arkansas
    • Colorado
    • Delaware
    • District of Columbia
    • California
    • Florida
    • Georgia
    • Hawaii
    • Idaho
    • Illinois
    • Kansas
    • Nebraska
    • Kentucky
    • Louisiana
    • Maine
    • Maryland
    • Massachusetts
    • Michigan
    • Minnesota
    • Mississippi
    • Missouri
    • Montana
    • Nevada
    • New Hampshire
    • New Jersey
    • Connecticut
    • New Mexico
    • New York
    • North Carolina
    • North Dakota
    • Oklahoma
    • Oregon
    • Pennsylvania
    • Rhode Island
    • South Carolina
    • South Dakota
    • Tennessee
    • Texas
    • Utah
    • Vermont
    • Virginia
    • Washington
    • West Virginia
    • Wisconsin
    • Wyoming

Status: In progress

In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation

  • Deadline to file a claim: 02/17/2024
  • Proof of Purchase Required: Yes
  • Potential Individual Reward: Varies
  • Total Settlement Amount: $30 million
  • Locations
    • Alabama
    • Alaska
    • Arizona
    • Arkansas
    • Colorado
    • Delaware
    • District of Columbia
    • California
    • Florida
    • Georgia
    • Hawaii
    • Idaho
    • Illinois
    • Kansas
    • Nebraska
    • Kentucky
    • Louisiana
    • Maine
    • Maryland
    • Massachusetts
    • Michigan
    • Minnesota
    • Mississippi
    • Missouri
    • Montana
    • Nevada
    • New Hampshire
    • New Jersey
    • Connecticut
    • New Mexico
    • New York
    • North Carolina
    • North Dakota
    • Oklahoma
    • Oregon
    • Pennsylvania
    • Rhode Island
    • South Carolina
    • South Dakota
    • Tennessee
    • Texas
    • Utah
    • Vermont
    • Virginia
    • Washington
    • West Virginia
    • Wisconsin
    • Wyoming

Status: In progress

In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation

The settlement benefits individuals and entities who indirectly purchased or paid for Suboxone and its AB-rated generic equivalents for themselves, their families, employees, plan participants, beneficiaries or insureds between Dec. 22, 201,1 and Aug. 21, 2023, in certain U.S. states.

  • Deadline to file a claim: 02/17/2024
  • Proof of Purchase Required: Yes
  • Potential Individual Reward: Varies
  • Total Settlement Amount: $30 million
  • Locations
    • Alabama
    • Alaska
    • Arizona
    • Arkansas
    • Colorado
    • Delaware
    • District of Columbia
    • California
    • Florida
    • Georgia
    • Hawaii
    • Idaho
    • Illinois
    • Kansas
    • Nebraska
    • Kentucky
    • Louisiana
    • Maine
    • Maryland
    • Massachusetts
    • Michigan
    • Minnesota
    • Mississippi
    • Missouri
    • Montana
    • Nevada
    • New Hampshire
    • New Jersey
    • Connecticut
    • New Mexico
    • New York
    • North Carolina
    • North Dakota
    • Oklahoma
    • Oregon
    • Pennsylvania
    • Rhode Island
    • South Carolina
    • South Dakota
    • Tennessee
    • Texas
    • Utah
    • Vermont
    • Virginia
    • Washington
    • West Virginia
    • Wisconsin
    • Wyoming

Status: In progress

In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation

The deadline to submit a claim has passed.

  • Deadline to file a claim: 02/17/2024
  • Proof of Purchase Required: Yes
  • Potential Individual Reward: Varies
  • Total Settlement Amount: $30 million
  • Locations
    • Alabama
    • Alaska
    • Arizona
    • Arkansas
    • Colorado
    • Delaware
    • District of Columbia
    • California
    • Florida
    • Georgia
    • Hawaii
    • Idaho
    • Illinois
    • Kansas
    • Nebraska
    • Kentucky
    • Louisiana
    • Maine
    • Maryland
    • Massachusetts
    • Michigan
    • Minnesota
    • Mississippi
    • Missouri
    • Montana
    • Nevada
    • New Hampshire
    • New Jersey
    • Connecticut
    • New Mexico
    • New York
    • North Carolina
    • North Dakota
    • Oklahoma
    • Oregon
    • Pennsylvania
    • Rhode Island
    • South Carolina
    • South Dakota
    • Tennessee
    • Texas
    • Utah
    • Vermont
    • Virginia
    • Washington
    • West Virginia
    • Wisconsin
    • Wyoming

By Top Class Actions  |  September 1, 2023

Category: Closed Class Actions

This settlement is closed!

Please see what other class action settlements you might qualify to claim cash from in our Open Settlements directory!

A Suboxone box, representing the Suboxone class action lawsuit settlement.
(Photo Credit: PureRadiancePhoto/Shutterstock)

Update:

  • Final approval for this class action settlement was granted Dec. 4, 2023.
  • Let Top Class Actions know when you receive a check in the comments section below or on our Facebook page.

Indivior agreed to a $30 million antitrust class action lawsuit settlement to resolve claims that it worked with other companies to raise the cost of Suboxone, a treatment for opioid addiction.

The settlement benefits individuals and entities who indirectly purchased or paid for Suboxone and its AB-rated generic equivalents for themselves, their families, employees, plan participants, beneficiaries or insureds between Dec. 22, 2011 and Aug. 21, 2023, in Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming and the District of Columbia.

The antitrust class action lawsuit accused Indivior of conspiring with other companies to raise the price of Suboxone and its generic alternatives. According to the plaintiffs in the case, they were forced to overpay for Suboxone as a result of the antitrust scheme. 

Individor is a pharmaceutical company that specializes in addiction and mental health treatment. 

Indivior hasn’t admitted any wrongdoing but agreed to a $30 million settlement to resolve the antitrust class action lawsuit.

Under the terms of the Suboxone class action settlement, class members can receive a proportional share of the net settlement fund based on the amount they spent in qualifying purchases. Exact payments will vary depending on the number of claims filed and other factors. 

The deadline for exclusion is Oct. 12, 2023. The objection deadline is Oct. 5, 2023.

The final approval hearing for the Suboxone antitrust class action lawsuit settlement is scheduled for Oct. 19, 2023.

In order to receive a settlement payment, class members must submit a valid claim form by Feb. 17, 2024.

Who’s Eligible

Individuals and entities who indirectly purchased or paid for Suboxone and its AB-rated generic equivalents for themselves, their families, employees, plan participants, beneficiaries or insureds between Dec. 22, 2011, and Aug. 21, 2023, in Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming and the District of Columbia

Potential Award

Varies

Proof of Purchase

Records from the class member’s pharmacy showing they purchased Suboxone and its AB‐rated generic equivalents at least once or a note or records from their doctor describing the amount of Suboxone and its AB‐rated generic equivalents prescribed.

Class members may have a claim even if they are not able to provide any of the above claim documentation as long as they provide the certification on the claim form. However, the settlement administrator may ask those who do not provide the above documentation for additional claim documentation after the class member submits their claim form. 

Claim Form

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

02/17/2024

Case Name

In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation, Case No. 2:13-md-02445-MSG, in the U.S. District Court for the Eastern District of Pennsylvania

Final Hearing

10/19/2023

Settlement Website
Claims Administrator

Suboxone End-Payor Antitrust Litigation
c/o A.B. Data, Ltd.
P.O. Box 173080
Milwaukee, WI 53217
[email protected]
877-311-3735

Class Counsel

Kenneth A Wexler
WEXLER BOLEY & ELGERSMA LLP

Steve Shadowen
HILLIARD SHADOWEN LLP

Michael M. Buchman
MOTLEY RICE LLC

Marvin A Miller
MILLER LAW LLC

Jeffrey L Kodroff
SPECTOR ROSEMAN & KODROFF PC

Defense Counsel

Justin Bernick
HOGAN LOVELLS US LLP

Read About More Class Action Lawsuits & Class Action Settlements:

We tell you about cash you can claim EVERY WEEK! Sign up for our free newsletter.

311 thoughts onSuboxone indirect purchasers antitrust $30M class action settlement

  1. Anthony says:

    Rescheduled — There is a new date for the court hearing set for 2/6/26 for the Motion for Disbursement of Funds to Authorize Distribution of the Net Settlement Funds. This was hearing was previously scheduled for 1/13/26 then 1/20/26.

  2. Jon Doe says:

    Yes, on 1/21/26 a new notice was posted for a hearing set for 2/6/2026 at 10:00 a.m. I wouldn’t hold your breath though as this has already been rescheduled two times prior (i.e., 1/13/26 and 1/20/26). Here is the real kick to the guts, on 11/23/23, the court approved payment of $13,942,771.87 for the attorneys and their expenses. No, your eyes did not just deceive you. Over two years ago, the attorneys were paid, yet the very people they represented, the one’s who were actually harmed by the inflated prices of Suboxone, are the ones still awaiting their payments. While at the same time the courts, attorneys, and AB Data continue to delay the hearings that would make payment possible. It is ludicrous. The money is there. In fact, it is earning interest. So the longer they hold it, the more interest is earned. Enough is enough. If we did our jobs the way they do their jobs, none of us would have jobs. Give me a break. I’m fed up with this.

    1. Rose says:

      I completely agree with u they been pushing it off and taking so much money out of it there gonna be nothing left for those who actually done wrong and deserve more of a claim. It’s getting ridiculous and why am I not surprised by this. They only want want want and it’s never enough but those like us who were hurt and took advantage by them will never get our due and if we do it chump change while they get rich off it

  3. John Doe says:

    Yes, on 1/21/26 a new notice was posted for a hearing on 2/6/2026 at 10:00 a.m. However, I wouldn’t hold your breath as this hearing has already been rescheduled two times prior (i.e., 1/13/26 and 1/20/26). Here is the real kick to the guts, on 11/23/23, the court approved payment of $13,942,771.87 for the attorneys and their expenses. No, your eyes did not just deceive you. Over two years ago, the courts authorized payment to the attorneys. Yet, the very people who these attorneys represented, from which they made their $14 million from, are still waiting — while the courts, attorneys, and AB Data continue to delay the hearings. But again, interest is being earned on the money that is sitting there waiting. Enough is enough. If we did our jobs the way they do their jobs, none of us would have jobs. I’m fed up with this BS.

  4. John Doe says:

    I would like to see a class action lawsuit filed against AB Data and the various law firms responsible for what I view as the inept handling of this case, causing unacceptable delays in processing payments to the actual individuals for whom this lawsuit is intended and for the confusion and often contradictory information/disinformation that they disseminated. The countless delays were one thing, but the inadequate and contradictory updates provided show, in my opinion, an intentional lack of transparency from these parties. I also find it appalling that they already received much of their payments from this lawsuit, while unnecessarily prolonging the process, and thus delaying the payments owed to the individuals who were long ago affected by the unreasonable prices they paid for Suboxone. Not only were these people already screwed because a drug company monopolized the market for a medicine used to treat OPIOD ADDICTION, but through the very class action lawsuit that is supposed to be helping them, is also screwing them over. Is it just me, or is it not absolutely insane that it was literally 15 years ago the that these prescriptions were purchased, and nearly 11 years ago the class action was filed. What a joke. Don’t get me wrong, I am thankful that the class action was brought, but I think it is disgraceful how it has been handled since. I believe the courts are just as much at fault for allowing something like this to occur. AB data blames the delays on the high numbers of fraudulent claims that were made. Are we to believe that this is an isolated situation with just this one class action lawsuit? Also, shouldn’t it be expected that AB data would have the tools in place to quickly address and weed out the fraudulent claims. This is literally the business they are in. If they weren’t prepared or lacked the capability to quickly handle such an issue, why were they selected by the courts to administer the payment. Lastly, I would like to know if the monies being held in escrow as they await being paid out were earning interest. If they were, how much interest was earned as a result of the countless delays? And, if interest was earned on that money, in the end who receives that additional money? Seems to me like there would be a significant financial interest to delay payments being made to the “little guy”, while interest is being accumulated on $30 million. Just saying.

    1. John says:

      Well said is there an update from 1/20/26 or did they delay again ?

      1. Rodnee Rayford says:

        Yes they said that it was rescheduled for 02/06/2026 on 01/21/2026, but yeah…well said and this is ridiculous!!!

  5. Anthony says:

    There is a new date for a court hearing set for 1/20/26 for the Motion for Disbursement of Funds to Authorize Distribution of the Net Settlement Funds.

    1. Larry says:

      It will be put off again . Y’all got paid now everyone else get what 25 dollars while y’all get rich .

  6. Leanne Long says:

    Im desperately seeking assistance. Im in Australia and longterm Suboxone patient and due to extreme dental &gum issues had all teeth removed and full dentures. Please advise any leads on Austrhalian legal firms or involvement in legal action.

    1. Rose says:

      Wrong lawsuit Google dental one

  7. Anthony says:

    There is another court date Jan 13, 2026 being held due to four claimants that have requested a “court review” of their claims. The Claims Administrator is requesting that at this court review that all four of these claims are rejected as they all exhibited “multiple, significant indicia of ineligibility” stating additionally that none of the four claimants had provided proper documentation with their claim submission. The Claims Administrator is additionally requesting at this court date (regardless of the outcome of the aforementioned four claim reviews) “that the Court authorize the distribution of the Net Settlement Fund to Eligible Claimants pursuant to the Court approved allocation plan”.

  8. Anthony says:

    Per the 12/10/25 posted documents, the Motion for Authorization to Distribute the Settlement Funds was approved making it “likely” that the payments will be distributed by the end of Feb, 2026 and maybe even sooner. It is important to note that the distribution plan changed from being a fractional payment based upon claim amount to a simple “pro rata”. This was likely done to expedite the distribution timeline. Out of the 10,300 total claims, it still has not been established what is the numeric breakdown of 10,300 between the number of Repealer and Non-Repealer claims making it impossible to firmly estimate the claim amounts. Roughly assuming a 90/10 split similar to the financial split (which is likely incorrect), that would result in approximately a $700-1000 payment per claim. If anyone has additional information on the Repealer/Non-Replealer claim numbers, please post it here. Thank you.

    1. J says:

      I hope it’s not split and they base it on claim amounts individually cause 700-1k compared my claim is pennies

      1. J says:

        There’s another court date set for Jan 12th so def late Feb or March

    2. Carrie wood says:

      Where did you see that the plan had changed? Just curious

1 12 13 14

Leave a Reply

Your email address will not be published. By submitting your comment and contact information, you agree to receive marketing emails from Top Class Actions regarding this and/or similar lawsuits or settlements, and/or to be contacted by an attorney or law firm to discuss the details of your potential case at no charge to you if you qualify. Required fields are marked *

Please note: Top Class Actions is not a settlement administrator or law firm. Top Class Actions is a legal news source that reports on class action lawsuits, class action settlements, drug injury lawsuits and product liability lawsuits. Top Class Actions does not process claims and we cannot advise you on the status of any class action settlement claim. You must contact the settlement administrator or your attorney for any updates regarding your claim status, claim form or questions about when payments are expected to be mailed out.